Cargando…

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib

Genomic studies are revolutionizing clinical oncology, but bridging the lab and the bedside requires the ability to efficiently interrogate rare genetic lesions in unexpected pathological settings using preclinical models. Oncogenes can exhibit intrinsic drug resistance to targeted therapy in differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gozgit, Joseph M., Chen, Tzu-Hsiu, Song, Youngchul, Wardwell, Scott, Wang, Frank, Cai, Jie, Li, Henry, Edgren, Henrik, Rivera, Victor M., Pritchard, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049858/ https://www.ncbi.nlm.nih.gov/pubmed/30038711 http://dx.doi.org/10.18632/oncotarget.25664

Ejemplares similares

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
por: Gainor, Justin F., et al.
Publicado: (2020)

Identification and characterization of RET fusions in advanced colorectal cancer
por: Le Rolle, Anne-France, et al.
Publicado: (2015)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
por: George, Suzanne, et al.
Publicado: (2022)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
por: Nagasaka, Misako, et al.
Publicado: (2023)

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells
por: SUN, YUE-LI, et al.
Publicado: (2014)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model
por: Flietner, Evan, et al.
Publicado: (2022)

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
por: Chen, Mengke, et al.
Publicado: (2023)

Reengineering Ponatinib to Minimize Cardiovascular Toxicity
por: Hnatiuk, Anna P., et al.
Publicado: (2022)

ALK, ROS1, RET and NTRK1–3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers
por: Mulkidjan, Rimma S., et al.
Publicado: (2023)

Eruptive melanocytic nevi associated with ponatinib
por: Devred, Inès, et al.
Publicado: (2018)

Ponatinib-Induced Cerebrovascular Accident (CVA)
por: Azad, Farhan, et al.
Publicado: (2022)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation
por: Li, Xian, et al.
Publicado: (2019)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth
por: Tan, Fiona H., et al.
Publicado: (2018)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines
por: Kim, Sun Young, et al.
Publicado: (2018)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
por: Fauster, A, et al.
Publicado: (2015)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.
por: Iwamoto, T., et al.
Publicado: (1993)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET Protein Expression in Colorectal Cancer; An Immunohistochemical Assessment
por: Ashkboos, Maryam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uv8j8jf8slk880v6qsvqs0iiua